Compare Credo Technology Group Holding Ltd (CRDO) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs GSK plc — how do they compare? Credo Technology Group Holding Ltd trades at $215.44 (market cap $39.82B), while GSK plc trades at $46.6 (market cap $91.88B). The key difference: GSK plc is far larger — about 2.3× Credo Technology Group Holding Ltd's market cap, and GSK plc pays a 3.9% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and GSK plc for 93 Days on average.
| CRDO | GSK | |
|---|---|---|
Market Cap | $39.82B | $91.88B |
Volume | 9,451,558 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $302.52 | $61.18 |
52-Week Low | $87.81 | $43.24 |
Typical Hold Time | 22 Days | 93 Days |
Enterprise Value | $39.08B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $213.95, down 2.75% today but maintains strong technical support near $214. The company demonstrates exceptional fundamental performance with 114.7% YoY revenue growth and 33.83% net margins. Recent earnings beats and bullish analyst consensus at 87.5% buy ratings support the positive outlook. Technical indicators show bullish moving averages while oscillators remain neutral, with key support at $204 and resistance at $222.
CRDO presents compelling growth potential driven by AI infrastructure demand, with consensus price target of $267.33 offering 25% upside. Risks include premium valuation (P/E 74.6) and customer concentration, but strong cash flow generation and expanding optical business provide fundamental support. The stock's recent pullback may offer entry opportunity for growth investors.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
